Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M

Phathom Pharmaceuticals, Inc.

8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.
Gross proceeds ~$130M; net proceeds ~$121.7M after underwriting discounts and expenses.
Offering expected to close August 20, 2024; use proceeds for commercialization and vonoprazan clinical development.
Joint bookrunners: Evercore ISI, Stifel, Guggenheim; co-managers: H.C. Wainwright, Needham, Craig-Hallum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.